Travere Therapeutics Inc
TVTXHealthcare|Biotechnology|USA
$56.60
-1.88 (-3.22%)
Clinical Trials (19)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07219121 Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | Proteinuria, Immunoglobulin A (IgA) Nephropathy | P4 | Active | 20 | Open-label | Sparsentan |
| NCT06247085 A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment | Homocystinuria | P3 | Recruiting | 70 | RCT, Double-blind | Pegtibatinase |
| NCT03762850 A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy | Immunoglobulin A Nephropathy | P3 | Active | 406 | RCT, Double-blind | sparsentan, irbesartan, Dapagliflozin |
| NCT04663204 A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy | Immunoglobulin A Nephropathy, Kidney Diseases | P2 | Recruiting | 24 | Open-label | Sparsentan |
| NCT03406611 Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE) | Homocystinuria | P1P2 | Active | 32 | RCT, Double-blind | Pegtibatinase, Placebo |
| NCT05003986 Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | Focal Segmental Glomerulosclerosis, Minimal Change Disease | P2 | Recruiting | 67 | Open-label | Sparsentan, Sparsentan, Sparsentan |
| NCT05630612 ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) | ANCA Associated Vasculitis, Cardiovascular Diseases | P2 | Active | 32 | RCT, Double-blind | Sparsentan |
| NCT02998710 Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA) | Homocystinuria Due to CBS Deficiency | Recruiting | 150 | — | — | |
| NCT03493685 Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis | P3 | Completed | 371 | RCT, Double-blind | sparsentan, Irbesartan |
| NCT03041116 Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants | Pantothenate Kinase-Associated Neurodegeneration | P3 | Terminated | 84 | RCT, Double-blind | Fosmetpantotenate, Placebo |
| NCT06431893 A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) | Homocystinuria | P3 | By Invite | 100 | Open-label | Pegtibatinase |
| NCT05856760 A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN | Immunoglobulin A Nephropathy | P2 | Completed | 48 | Open-label | Sparsentan |
| NCT01613118 Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | P2 | Completed | 109 | RCT, Double-blind | RE-021 (Sparsentan), Irbesartan |
| NCT07224776 Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria | Proteinuric Renal Disease, Proteinuric Kidney Disease | P1 | Not Yet Recruiting | 20 | Open-label | sparsentan, No sparsentan |
| NCT05562362 Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension | Healthy Subjects | P1 | Completed | 47 | RCT, Open-label | RE-021, sparsentan |
| NCT06548022 Rare Group Problem Management Plus | Anxiety, Depressive Symptoms | N/A | Completed | 8 | Open-label | — |
| NCT02638220 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study | Cerebrotendinous Xanthomatosis (CTX) | Completed | 442 | — | — | |
| NCT05368038 ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2 | By Invite | 100,000 | — | — | |
| NCT05200871 Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) | Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy | Completed | 487 | — | — |